Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
RALT gene loss impedes the efficacy of HER-2 inhibitor
August 25th, 2005
RALT gene loss impedes the efficacy of HER-2 inhibitor. According to recent research published in the journal Oncogene, "an emerging paradigm holds that loss of negative signaling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells." "Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signaling in breast epithelium may represent an advantageous condition during ErbB-driven...
Source: Women's Health Weekly (2005-08-25)
|
